Objective To observe the impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome(MS) to collect data on safety of rosuvastatin in treating MS.Methods Eighty MS patients were enrolled and divided into the treatment group(n =40) and the control group(n =40).The treatment group received both antihypertensive therapy and rosuvastatin with a dose of 10 mg/d.While the control group were only given antihypertensive therapy and but not any lipid-lowering drugs.The levels of plasma Ang-2 and hs-CRP and liver and kidney functions were measured and compared before and after 8-week treatment.Results (1) The levels of plasma Ang-2 and hs-CRP were significantly lower after 8 weeks than before treatment in the treatment groups[Ang-2:(0.30±0.01) μg/L vs.(1.81±0.47) μg/L,t =9.02,P ＜0.01 ;hs-CRP:(2.02±0.26) mg/L vs.(6.32±1.28) mg/L,t =5.75,P ＜ 0.01].Whereas statistical difference was not found in the control group[Ang-2:(1.80±0.45) μg/L vs.(1.79±0.48) μg/L,t =0.19,P > 0.05 ; hs-CRP:(6.28±1.34) mg/L vs.(6.20±1.42) mg/L,t =0.23,P ＞ 0.05].(2) After 8 weeks'treatment,the levels of plasma Ang-2 and hs-CRP were significantly lower in the treatment group than in the control group[Ang-2:(0.30±0.01) μg/L vs.(1.79±0.48) μμg/L,t =2.34,P ＜ 0.05 ;(2.02±0.26) mg/Lvs.(6.20±1.42) mg/L,t =2.58,P ＜ 0.05].(3) The adverse reaction in the treatment group was fewer than the control group and the security of rosuvastatin treatment on MS was fine.Conclusion Rosuvastatin can reduce plasma Ang-2 and hs-CRP levels and improve insulin resistance in patients with MS.Its security is fine.

Objective To investigate the efficacy of rosuvastatin on treating patients with metabolic syndrome(MS).Methods Eighty MS patients were divided into rosuvastatin group (n =40) and atorvastatin group(n =40).Patients in rosuvastatin group were received schufftan at dose of 10 mg/d and in atorvastatin group were received lipitor at dose of 10 mg/d orally.Patients were followed-up for 12 weeks.The ratio of apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) and inflammatory factors including high-sensitivity Czreactive protein (hs-CRP),tumor necrosis factor-oα (TNF-α),interleukin-6 (IL-6),and interleukin-18 (IL-18) were measured.Meanwhile Secondary factors:blood lipids,blood glucose,fasting insulin (FIN),insulin resistance index (HOMA-IR),blood pressure,urine albumin excretion rate (UAER),body mass index (BMI).As well as safety indicators:hepatic and renal function and creatine kinase (CK) were detected.Results (1) After 12-week's treatment,the serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),triglyceride (TG),FIN,HOMA-IR,systolic blood pressure (SBP),diastolic blood pressure (DBP),and UAER significantly decreased compared to before treatment in the two groups(rosuvastatin group:1.26 ± 0.25 vs.0.63 ± 0.22,t =4.44 ; (6.89 ± 1.43) mg/L vs.(2.41 ± 0.36) mg/L,t =7.12;(27.63 ±7.12) ng/L vs.(12.98 ±3.74) ng/L,t =4.23;(26.47 ±6.59) ng/L vs.(13.16± 3.55) ng/L,t =4.45;(318.36 ±90.45) ng/L vs.(172.77 ±50.65) ng/L,t =3.92;(1.58 ±0.29) g/L vs.(0.83 ± 0.23) g/L,t =4.20; (5.78 ± 0.86) mmol/L vs.(3.53 ± 0.69) mmol/L,t =3.85 ; (3.52 ± 0.54) mmol/L vs.(2.04±0.49) mmol/L,t =3.89;(2.87 ±0.65) mmol/L vs.(1.91 ±0.57) mmol/L,t =3.78; (12.08 ± 2.87) mU/L vs.(6.87 ± 1.89) mU/L,t =3.98 ; 3.42 ± 0.57 vs.1.60 ± 0.31,t =4.65 ; (144.6 ± 13.3) mm Hg vs.(135.1 ±12.7) mm Hg,t =3.57;(93.6 ±9.5) mm Hg vs.(85.2 ±7.6) mm Hg,t =3.59; (29.86 ± 3.37) μg/min vs.(22.52 ± 2.56) μg/min,t =3.71 ; atorvastatin group:1.24 ± 0.23 vs.0.92 ± 0.24,t =3.74 ; (6.84 ± 1.37) mg/L vs.(3.50 ± 0.75) mg/L,t =4.24 ; (27.22 ± 7.36) ng/L vs.(18.70 ± 5.82) ng/L,t =3.76; (26.28 ±6.84) ng/L vs.(19.34 ± 5.96) ng/L,t =3.75 ; (311.22 ±91.98) ng/L vs.(246.50±74.73) ng/L,t=3.63;(1.56±0.27) g/L vs.(1.14±0.26) g/L,t =3.74;(5.65 ±0.76) mmol/L vs.(4.67±0.65) mmol/L,t =3.68;(3.51 ±0.55) mmol/L vs.(2.65 ±0.57) mmol/L,t =3.70; (2.86±0.68) mmol/Lvs.(2.05 ±0.54) mmol/L,t=3.78;(12.04±2.95) mU/L vs.(8.91 ±2.32) mU/L,t =3.74;3.38 ±0.54 vs.2.18 ±0.35,t =3.80;(144.0 ± 13.8) mm Hg vs.(135.7 ±12.5) mm Hg,t =3.56 ; (93.4 ± 9.3) mm Hg vs.(85.8 ± 8.9) mm Hg,t =3.58 ; (29.77 ± 3.28) μg/min vs.(23.02 ± 2.83) μg/min,t =3.67 ;P ＜ 0.01).ApoA1 and high-density lipoprotein cholesterol (HDL-C) had increase,but there was no significant difference(P ＞ 0.05).Fasting plasma glucose(FPG),2 h postprandial blood glucose (2 hPG) and BMI tended to decrease,but there were no significant differences(P ＞ 0.05).(2)The serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,TC,LDL-C,FIN and HOMA-IR in the rosuvastatin group were significantly lower than those in the atorvastatin group at the 12th-week follow-up(t =2.11,2.10,2.09,2.12,2.08,2.07,2.05,2.04,2.04,2.06 respectively; P ＜ 0.05).The serum levels of HDL-C and ApoA1 in the rosuvastatin group tended to increase compared with the atorvastatin group after 12-week treatment (P ＞ 0.05).There were no statistically significant differences in term of TG,SBP,DBP,UAER between the two groups (P ＞ 0.05).(3) The adverse effect in the rosuvastatin group was fewer than that in atorvastatin group.Conclusion Rosuvastatin can reduce ApoB/ApoA1 ratio and the levels of inflammatory cytokines,improve insulin resistance in patients with MS and less adverse effect were seen.

Aged ; Diabetes Mellitus, Type 2 ; therapy ; Humans ; Walking

Congenital dilatation of the common bile duct is relatively rare anomaly. Its pathogenesis has not been completely understood. Complications of the choledochal cyst are mainly suppurative cholangitis, liver cirrhosis, stone formation, malignant change, bile peritonitis due to spontaneous and traumatic rupture. We experienced one case of choledochal cyst associated with hemorrhagic tendency and a cerebral hematoma, which is extremely rare complication. The 3 months old male patient reported here was treated with complete excision of cyst and Roux-en-Y choledochojejunostomy after correction of bleeding tendency and removal of cerebral hematoma. Postoperative course was relatively uneventful. 11 days after operation, the patient was discharged with full improvement.
Bile ; Cholangitis ; Choledochal Cyst* ; Choledochostomy ; Common Bile Duct ; Dilatation ; Hematoma* ; Hemorrhage ; Humans ; Liver Cirrhosis ; Male ; Peritonitis ; Rupture

Indoor transfer lift is a useful technical assistant to assist the nursing of mobility impaired person, and the high-end product even make it possible that the disabled to live an independent living. The features of market available transfer lifts are discussed and the standard ISO 10535 (Hoists for the transfer of disabled persons--Requirements and test methods) is briefly introduced. The component parts and their function of rail lift are introduced in detail.
Disabled Persons ; rehabilitation ; Humans ; Moving and Lifting Patients ; instrumentation ; Self Care ; instrumentation ; Self-Help Devices

OBJECTIVETo study the severe acute respiratory syndrome (SARS)-associated coronavirus genotype and its characteristics.

METHODSA SARS-associated coronavirus isolate named ZJ01 was obtained from throat swab samples taken from a patient in Hangzhou, Zhejing province. The complete genome sequence of ZJ01 consisted of 29,715 bp (GenBank accession: AY297028, version: gi: 30910859). Seventeen SARS-associated coronavirus genome sequences in GenBank were compared to analyze the common sequence variations and the probability of co-occurrence of multiple polymorphisms or mutations. Phylogenetic analysis of those sequences was done.

RESULTSBy bioinformatics processing and analysis, the 5 loci nucleotides at ZJ01 genome were found being T, T, G, T and T, respectively. Compared with other SARS-associated coronavirus genomes in the GenBank database, an A/G mutation was detected besides the other 4 mutation loci (C:G:C:C/T:T:T:T) involved in this genetic signature. Therefore a new definition was put forward according to the 5 mutation loci. SARS-associated coronavirus strains would be grouped into two genotypes (C:G:A:C:C/T:T:G:T:T), and abbreviated as SARS coronavirus C genotype and T genotype. On the basis of this new definition, the ZJ01 isolate belongs to SARS-associated coronavirus T genotype, first discovered and reported in mainland China. Phylogenetic analysis of the spike protein gene fragments of these SARS-associated coronavirus strains showed that the GZ01 isolate was phylogenetically distinct from other isolates, and compared with groups F1 and F2 of the T genotype, the isolates of BJ01 and CUHK-W1 were more closely related to the GZ01 isolate. It was interesting to find that two (A/G and C/T) of the five mutation loci occurred in the spike protein gene, which caused changes of Asp to Gly and Thr to Ile in the protein, respectively.

CONCLUSIONAttention should be paid to whether these genotype and mutation patterns are related to the virus's biological activities,epidemic characteristics and host clinical symptoms.

Genotype ; Humans ; Middle Aged ; Mutation ; SARS Virus ; genetics